Cerus Stock Price, News & Analysis (NASDAQ:CERS)

$4.18 +0.02 (+0.48 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$4.16
Today's Range$4.16 - $4.32
52-Week Range$1.93 - $5.43
Volume590,727 shs
Average Volume1.75 million shs
Market Capitalization$513.83 million
P/E Ratio-7.17
Dividend YieldN/A
Beta2.22

About Cerus (NASDAQ:CERS)

Cerus logoCerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Debt-to-Equity Ratio0.80%
Current Ratio3.71%
Quick Ratio3.11%

Price-To-Earnings

Trailing P/E Ratio-7.16937001067779
Forward P/E Ratio-7.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.28 million
Price / Sales13.24
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book7.46

Profitability

Trailing EPS($0.59)
Net Income$-62,900,000.00
Net Margins-159.35%
Return on Equity-142.18%
Return on Assets-67.72%

Miscellaneous

Employees204
Outstanding Shares124,410,000

Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.12) EPS for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.03. The biotechnology company earned $10.80 million during the quarter, compared to analysts' expectations of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. Cerus's revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.14) EPS. View Cerus' Earnings History.

When will Cerus make its next earnings announcement?

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Cerus.

Where is Cerus' stock going? Where will Cerus' stock price be in 2018?

5 Wall Street analysts have issued 12-month price objectives for Cerus' stock. Their predictions range from $5.00 to $10.00. On average, they expect Cerus' share price to reach $6.20 in the next twelve months. View Analyst Ratings for Cerus.

What are Wall Street analysts saying about Cerus stock?

Here are some recent quotes from research analysts about Cerus stock:

  • 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (1/30/2018)
  • 2. Cantor Fitzgerald analysts commented, "This afternoon, CERS announced that its Ph 3 transfusion study (SPARC) evaluating its INTERCEPT-treated red blood cells in thalassemia (chronic anemia) patients achieved its primary efficacy and safety endpoints." (1/23/2018)

Who are some of Cerus' key competitors?

Who are Cerus' key executives?

Cerus' management team includes the folowing people:

  • Daniel N. Swisher Jr., Independent Chairman of the Board (Age 54)
  • William M. Greenman, President, Chief Executive Officer, Director (Age 50)
  • Kevin Dennis Green, Chief Financial Officer, Vice President - Finance (Age 44)
  • Caspar Hogeboom, President, Cerus Europe and EEMEA (Age 56)
  • Laurence M. Corash M.D., Senior Vice President, Chief Medical and Chief Scientific Officer, Director (Age 71)
  • Carol M. Moore, Senior Vice President - Regulatory Affairs, Quality and Clinical (Age 65)
  • Richard J. Benjamin, Chief Medical Officer
  • Vivek K. Jayaraman, Chief Commercial Officer (Age 41)
  • Chrystal N. Menard, Chief Legal Officer and General Counsel (Age 44)
  • Timothy Bruce Anderson, Independent Director (Age 68)

Who owns Cerus stock?

Cerus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.82%), ARK Investment Management LLC (2.87%), Senvest Management LLC (2.55%), Peregrine Capital Management LLC (2.46%), Bamco Inc. NY (0.86%) and Geode Capital Management LLC (0.80%). Company insiders that own Cerus stock include Carol Moore, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Who sold Cerus stock? Who is selling Cerus stock?

Cerus' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Wells Fargo & Company MN, TIAA CREF Investment Management LLC, Raymond James & Associates, Rhumbline Advisers and Berson & Corrado Investment Advisors LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Who bought Cerus stock? Who is buying Cerus stock?

Cerus' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Millennium Management LLC, Bamco Inc. NY, Millrace Asset Group Inc., Goldman Sachs Group Inc., Senvest Management LLC, BlackRock Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Cerus.

How do I buy Cerus stock?

Shares of Cerus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of Cerus stock can currently be purchased for approximately $4.18.

How big of a company is Cerus?

Cerus has a market capitalization of $513.83 million and generates $39.28 million in revenue each year. The biotechnology company earns $-62,900,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Cerus employs 204 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (CERS)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cerus (NASDAQ:CERS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.803.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.20$6.20$7.00$7.25
Price Target Upside: 23.75% upside61.46% upside131.79% upside208.51% upside

Cerus (NASDAQ:CERS) Consensus Price Target History

Price Target History for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2018BTIG ResearchReiterated RatingHoldLowView Rating Details
1/23/2018Cantor FitzgeraldReiterated RatingBuy$5.00HighView Rating Details
12/1/2017Robert W. BairdReiterated RatingBuy$5.00LowView Rating Details
10/5/2017CowenSet Price TargetBuy$6.00N/AView Rating Details
3/8/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Cerus (NASDAQ:CERS) Earnings History and Estimates Chart

Earnings by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018        
11/2/2017Q3 2017($0.15)($0.12)$11.95 million$10.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.16)($0.16)$9.14 million$9.53 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.17)($0.18)$8.98 million$7.01 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.16)($0.13)$11.29 million$10.10 millionViewListenView Earnings Details
11/3/2016Q316($0.17)($0.14)$10.34 million$10.20 millionViewN/AView Earnings Details
8/4/2016Q216($0.17)($0.18)$8.88 million$9.25 millionViewN/AView Earnings Details
5/3/2016Q1($0.16)($0.17)$8.29 million$7.60 millionViewN/AView Earnings Details
3/8/2016Q415($0.16)($0.15)$9.72 million$9.70 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.17)$10.00 million$8.04 millionViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.17)$8.71 million$8.83 millionViewN/AView Earnings Details
5/5/2015Q214($0.16)($0.21)$7.70 million$7.70 millionViewN/AView Earnings Details
2/26/2015Q114($0.15)($0.25)$10.36 million$9.70 millionViewN/AView Earnings Details
11/4/2014Q413($0.13)($0.15)$9.83 million$10.36 millionViewN/AView Earnings Details
7/31/2014Q313($0.13)($0.16)$8.17 million$8.60 millionViewN/AView Earnings Details
5/1/2014Q313($0.09)($0.04)$9.65 million$7.86 millionViewN/AView Earnings Details
2/25/2014Q213($0.09)($0.10)$11.77 million$9.23 millionViewN/AView Earnings Details
10/29/2013($0.09)($0.29)$10.34 million$10.54 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.09)($0.10)$10.45 million$10.15 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.08)($0.11)$9.96 million$9.73 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.08)($0.11)ViewN/AView Earnings Details
11/7/2012Q3 2012($0.08)($0.10)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.08)($0.17)ViewN/AView Earnings Details
5/1/2012Q1 2012($0.08)($0.08)ViewN/AView Earnings Details
2/28/2012Q4 2011($0.08)($0.09)ViewN/AView Earnings Details
11/1/2011Q3 2011($0.10)($0.06)ViewN/AView Earnings Details
7/28/2011Q2 2011($0.10)($0.13)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.09)($0.11)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.07)($0.05)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.09)($0.10)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.11)($0.14)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.10)($0.13)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.12)($0.13)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.12)($0.16)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.16)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.18)($0.21)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.24)($0.20)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.27)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.26)($0.28)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.26)($0.16)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.25)($0.32)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cerus (NASDAQ:CERS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.57 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Cerus (NASDAQ:CERS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cerus (NASDAQ CERS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 54.73%
Insider Trades by Quarter for Cerus (NASDAQ:CERS)
Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2017Laurence M CorashInsiderBuy92,796$2.45$227,350.201,375,711View SEC Filing  
3/15/2017Kevin Dennis GreenCFOSell2,343$4.21$9,864.03View SEC Filing  
3/15/2017William Mariner GreenmanInsiderSell8,786$4.21$36,989.06View SEC Filing  
3/14/2017Carol MooreSVPSell2,377$4.15$9,864.55View SEC Filing  
3/14/2017Richard J BenjaminInsiderSell1,189$4.15$4,934.353,000View SEC Filing  
8/22/2016Kevin Dennis GreenCFOSell17,150$6.80$116,620.00View SEC Filing  
8/19/2015Laurence M CorashInsiderBuy25,900$4.99$129,241.001,270,256View SEC Filing  
8/18/2015Laurence M CorashInsiderBuy84,600$4.77$403,542.00View SEC Filing  
11/10/2014William Mariner GreenmanCEOBuy21,800$3.93$85,674.00View SEC Filing  
11/19/2012William Mariner GreenmanCEOBuy3,200$3.02$9,664.00View SEC Filing  
11/16/2012Laurence M CorashInsiderBuy2,000$2.85$5,700.00View SEC Filing  
11/16/2012William Mariner GreenmanCEOBuy13,800$2.85$39,330.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cerus (NASDAQ CERS) News Headlines

Source:
DateHeadline
Cerus (CERS) versus Obalon Therapeutics (OBLN) Head-To-Head ContrastCerus (CERS) versus Obalon Therapeutics (OBLN) Head-To-Head Contrast
www.americanbankingnews.com - February 14 at 5:06 AM
Cerus Co. (CERS) Given Average Recommendation of "Hold" by AnalystsCerus Co. (CERS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 13 at 11:48 AM
 Analysts Expect Cerus Co. (CERS) to Announce -$0.12 Earnings Per Share Analysts Expect Cerus Co. (CERS) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - February 12 at 11:10 PM
Contrasting Cerus (CERS) & Amedica (AMDA)Contrasting Cerus (CERS) & Amedica (AMDA)
www.americanbankingnews.com - February 6 at 9:14 AM
Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters Option to ... - Business Wire (press release)Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter's Option to ... - Business Wire (press release)
www.businesswire.com - February 3 at 3:55 PM
Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional SharesCerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - February 3 at 9:37 AM
Cerus Announces Pricing of Public Offering of Common Stock - Business Wire (press release)Cerus Announces Pricing of Public Offering of Common Stock - Business Wire (press release)
www.businesswire.com - February 2 at 9:48 AM
Mid-Morning Market Update: Markets Open Higher; Boeing Beats Q4 EstimatesMid-Morning Market Update: Markets Open Higher; Boeing Beats Q4 Estimates
www.nasdaq.com - February 1 at 3:50 PM
Mid-Day Market Update: Cascadian Therapeutics Jumps Following Acquisition News; Bellicum Pharmaceuticals Shares PlungeMid-Day Market Update: Cascadian Therapeutics Jumps Following Acquisition News; Bellicum Pharmaceuticals Shares Plunge
www.nasdaq.com - January 31 at 3:51 PM
Cerus Announces Pricing of Public Offering of Common StockCerus Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 31 at 10:11 AM
Cerus Announces Public Offering of Common StockCerus Announces Public Offering of Common Stock
finance.yahoo.com - January 31 at 10:11 AM
Cerus (CERS) Downgraded to "Sell" at Zacks Investment ResearchCerus (CERS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 30 at 8:38 PM
Financial Analysis: Uroplasty (UPI) versus Cerus (CERS)Financial Analysis: Uroplasty (UPI) versus Cerus (CERS)
www.americanbankingnews.com - January 29 at 11:20 AM
Cerus Co. (CERS) Forecasted to Earn FY2017 Earnings of ($0.62) Per ShareCerus Co. (CERS) Forecasted to Earn FY2017 Earnings of ($0.62) Per Share
www.americanbankingnews.com - January 29 at 1:26 AM
Cerus (CERS) Given Hold Rating at BTIG ResearchCerus (CERS) Given Hold Rating at BTIG Research
www.americanbankingnews.com - January 25 at 12:16 PM
Cerus (CERS) Announces Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia PatientsCerus (CERS) Announces Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia Patients
www.streetinsider.com - January 24 at 4:01 PM
Cerus shares rise on positive late-stage results for anemia therapyCerus shares rise on positive late-stage results for anemia therapy
finance.yahoo.com - January 24 at 4:01 PM
Here's Why Cerus Corporation Stock Popped TodayHere's Why Cerus Corporation Stock Popped Today
finance.yahoo.com - January 24 at 4:01 PM
Heres Why Cerus Corporation Stock Popped TodayHere's Why Cerus Corporation Stock Popped Today
www.fool.com - January 24 at 2:11 PM
After-Hours Stock Movers 01/23: (CERS) (ARAY) (TSS) Higher; (PBYI) (TXN) (UAL) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 01/23: (CERS) (ARAY) (TSS) Higher; (PBYI) (TXN) (UAL) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 24 at 8:16 AM
Cerus (CERS) Announces Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red ... - StreetInsider.comCerus (CERS) Announces Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red ... - StreetInsider.com
www.streetinsider.com - January 24 at 8:16 AM
AMRN Looks Forward To Big Event, PBYI Plunges After-hours, SPARC Lights Up CERS - NasdaqAMRN Looks Forward To Big Event, PBYI Plunges After-hours, SPARC Lights Up CERS - Nasdaq
www.nasdaq.com - January 24 at 8:16 AM
Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia PatientsCerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia Patients
finance.yahoo.com - January 23 at 5:17 PM
Cerus Co. (CERS) Given Average Rating of "Hold" by BrokeragesCerus Co. (CERS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 19 at 9:58 AM
Cantor Fitzgerald Weighs in on Cerus Co.s FY2017 Earnings (CERS)Cantor Fitzgerald Weighs in on Cerus Co.'s FY2017 Earnings (CERS)
www.americanbankingnews.com - January 10 at 6:56 AM
Cerus (CERS) Announces Prelim. Product Revenue Results for Q4Cerus (CERS) Announces Prelim. Product Revenue Results for Q4
www.streetinsider.com - January 8 at 5:28 PM
Cerus (CERS) Given a $5.00 Price Target by Cantor Fitzgerald AnalystsCerus (CERS) Given a $5.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - January 8 at 11:18 AM
Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017
finance.yahoo.com - January 8 at 9:48 AM
Cerus (CERS) Stock Rating Reaffirmed by Cantor FitzgeraldCerus (CERS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - January 6 at 11:50 PM
Cerus (CERS) Lifted to Sell at BidaskClubCerus (CERS) Lifted to Sell at BidaskClub
www.americanbankingnews.com - January 6 at 12:30 PM
Cerus (CERS) Upgraded at ValuEngineCerus (CERS) Upgraded at ValuEngine
www.americanbankingnews.com - January 4 at 10:32 PM
Cerus (CERS) Downgraded by Zacks Investment ResearchCerus (CERS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 3 at 10:46 PM
Should You Buy Cerus Corporation (NASDAQ:CERS) At $3.56?Should You Buy Cerus Corporation (NASDAQ:CERS) At $3.56?
finance.yahoo.com - January 3 at 5:26 PM
BidaskClub Lowers Cerus (CERS) to Strong SellBidaskClub Lowers Cerus (CERS) to Strong Sell
www.americanbankingnews.com - December 29 at 11:56 AM
Cerus Corp. :CERS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Cerus Corp. :CERS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 28 at 3:51 PM
Cerus Corp. breached its 50 day moving average in a Bearish Manner : CERS-US : December 28, 2017Cerus Corp. breached its 50 day moving average in a Bearish Manner : CERS-US : December 28, 2017
finance.yahoo.com - December 28 at 3:51 PM
ETFs with exposure to Cerus Corp. : December 27, 2017ETFs with exposure to Cerus Corp. : December 27, 2017
finance.yahoo.com - December 28 at 3:51 PM
Cerus Co. (CERS) Given Consensus Rating of "Hold" by BrokeragesCerus Co. (CERS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 10:04 AM
Should You Invest In The Oil & Gas Stock Cerus Energy Group Ltd (CVE:CEA)?Should You Invest In The Oil & Gas Stock Cerus Energy Group Ltd (CVE:CEA)?
finance.yahoo.com - December 19 at 5:22 PM
Cerus (CERS) Stock Rating Lowered by BidaskClubCerus (CERS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 17 at 5:58 PM
Does Cerus Energy Group Ltd’s (CVE:CEA) Recent Track Record Look Strong?Does Cerus Energy Group Ltd’s (CVE:CEA) Recent Track Record Look Strong?
finance.yahoo.com - December 12 at 5:49 PM
Cerus (CERS) vs. Its Rivals Critical AnalysisCerus (CERS) vs. Its Rivals Critical Analysis
www.americanbankingnews.com - December 9 at 11:42 PM
Cerus (CERS) "Neutral" Rating Reaffirmed at BTIG ResearchCerus' (CERS) "Neutral" Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - December 8 at 6:08 PM
Head-To-Head Review: Cerus (CERS) versus The CompetitionHead-To-Head Review: Cerus (CERS) versus The Competition
www.americanbankingnews.com - December 7 at 9:38 PM
Cerus (CERS) versus Its Competitors Financial AnalysisCerus (CERS) versus Its Competitors Financial Analysis
www.americanbankingnews.com - December 6 at 7:25 PM
Contrasting Cerus (CERS) & Its PeersContrasting Cerus (CERS) & Its Peers
www.americanbankingnews.com - December 6 at 7:24 PM
Head-To-Head Analysis: Cerus (CERS) versus Its RivalsHead-To-Head Analysis: Cerus (CERS) versus Its Rivals
www.americanbankingnews.com - December 5 at 9:26 PM
Cerus (CERS) vs. Its Competitors Critical ComparisonCerus (CERS) vs. Its Competitors Critical Comparison
www.americanbankingnews.com - December 4 at 8:44 AM
Contrasting Cerus (CERS) and Its RivalsContrasting Cerus (CERS) and Its Rivals
www.americanbankingnews.com - December 4 at 1:34 AM
Cerus (CERS) Given Buy Rating at Robert W. BairdCerus (CERS) Given Buy Rating at Robert W. Baird
www.americanbankingnews.com - December 1 at 8:38 PM

SEC Filings

Cerus (NASDAQ:CERS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cerus (NASDAQ:CERS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cerus (NASDAQ CERS) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.